Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Revance The stock

Learn how to easily invest in Revance The stock.

Revance The is a biotechnology business based in the US. Revance The shares (RVNC) are listed on the NASDAQ and all prices are listed in US Dollars. Revance The employs 534 staff and has a trailing 12-month revenue of around $186.4 million.

How to buy Revance The stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – RVNC. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Promoted for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 in stock when you fund a new account within 30 days

Promoted for social trading

Finder Award


  • Easy to use platform with $0 stock trading & no annual fees
  • Social trading allows you to copy popular portfolios
  • FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100

Promoted for active trading


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+

Revance The stock price (NASDAQ: RVNC)

Use our graph to track the performance of RVNC stocks over time.

Revance The shares at a glance

Information last updated 2023-09-26.
Latest market close$12.09
52-week range$11.10 - $37.98
50-day moving average $18.94
200-day moving average $26.86
Wall St. target price$37.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-4.57

Buy Revance The stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 6 of 6
Name Product Ratings Available asset types Minimum deposit Signup bonus
SoFi Invest
Finder Rating: 4.6 / 5: ★★★★★

Finder Award
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000 in stock
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Rating: 4.2 / 5: ★★★★★

Finder Award
Stocks, Options, ETFs, Cryptocurrency
FINDER EXCLUSIVE: Get a guaranteed $15 bonus
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Finder Rating: 4.1 / 5: ★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures
Get $100 - $2,000
when you you open and fund an account with $5,000 to $100,000+
Highly commended for Best Derivatives Trading Platform award.
Finder Rating: 4 / 5: ★★★★★
Stocks, ETFs, Cryptocurrency, Art, Treasury Bills, Collectibles
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
2.5% fee applies to all alternative asset transactions.
Finder Rating: 4.2 / 5: ★★★★★
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4.9% interest on uninvested cash in your account with Robinhood Gold.
Finder Rating: 4 / 5: ★★★★★
Stocks, ETFs
Wealthfront builds a free financial plan for the life you want and automate your investments at a low cost.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Is it a good time to buy Revance The stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Revance The price performance over time

Historical closes compared with the close of $12.09 from 2023-09-27

1 week (2023-09-21) -3.05%
1 month (2023-08-28) -33.90%
3 months (2023-06-28) -52.40%
6 months (2023-03-28) -61.48%
1 year (2022-09-28) -51.52%
2 years (2021-09-28) -57.83%
3 years (2020-09-28) 25.99
5 years (2018-09-28) 24.85

Revance The financials

Revenue TTM $186.4 million
Gross profit TTM $-20,388,000
Return on assets TTM -29.72%
Return on equity TTM -2962.17%
Profit margin -191.93%
Book value $0.31
Market Capitalization $1.1 billion

TTM: trailing 12 months

Revance The share dividends

We're not expecting Revance The to pay a dividend over the next 12 months.

Revance The share price volatility

Over the last 12 months, Revance The's shares have ranged in value from as little as $11.1 up to $37.98. A popular way to gauge a stock's volatility is its "beta".

RVNC.US volatility(beta: 0.8)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Revance The's is 0.8005. This would suggest that Revance The's shares are less volatile than average (for this exchange).

Revance The overview

Revance Therapeutics, Inc. , a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids; and OPUL Relational Commerce Platform, a financial technology platform. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA.

Frequently asked questions

What percentage of Revance The is owned by insiders or institutions?
Currently 2.439% of Revance The shares are held by insiders and 97.124% by institutions.
How many people work for Revance The?
Latest data suggests 534 work at Revance The.
When does the fiscal year end for Revance The?
Revance The's fiscal year ends in December.
Where is Revance The based?
Revance The's address is: 1222 Demonbreun Street, Nashville, TN, United States, 37203
What is Revance The's ISIN number?
Revance The's international securities identification number is: US7613301099
What is Revance The's CUSIP number?
Revance The's Committee on Uniform Securities Identification Procedures number is: 761330109

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site